Curcumin interrupts the interaction between the androgen receptor and Wnt/β-catenin signaling pathway in LNCaP prostate cancer cells

Prostate Cancer and Prostatic Diseases

Volumn 13, Issue 4, 2010, Pages 343-349

  Choi, H Y ^a   Lim, J E ^a   Hong, J H ^b  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Dankook University   (South Korea)

Author keywords

catenin; androgen receptor; curcumin

Indexed keywords

ANDROGEN RECEPTOR; BETA CATENIN; CURCUMIN; CYCLIN D1; GLYCOGEN SYNTHASE KINASE 3BETA; MYC PROTEIN; PROTEIN KINASE B; T CELL FACTOR PROTEIN; WNT PROTEIN;

ARTICLE; CELL NUCLEUS; CELL STRAIN LNCAP; CELLULAR DISTRIBUTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; BETA CATENIN; CELL LINE, TUMOR; CELL NUCLEUS; CELL PROLIFERATION; CURCUMIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; HUMANS; MALE; PROSTATIC NEOPLASMS; PROTEIN BINDING; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; WNT1 PROTEIN;

EID: 78649322736     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2010.26     Document Type: Article

References (29)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-249.
2. Hebert JR, Hurley TG, Olendzki BC, Teas J, Ma Y, Hampl JS. Nutritional and socioeconomic factors in relation to prostate cancer mortality: a cross-national study. J Natl Cancer Inst 1998; 90: 1637-1647.
3. Rahman M, Miyamoto H, Chang C. Androgen receptor coregulators in prostate cancer: mechanisms and clinical implications. Clin Cancer Res 2004; 10: 2208-2219.
4. Verras M, Sun Z. Roles and regulation of Wnt signaling and beta-catenin in prostate cancer. Cancer Lett 2006; 237: 22-32.
5. Truica CI, Byers S, Gelmann EP. Beta-catenin affects androgen receptor transcriptional activity and ligand specificity. Cancer Res 2000; 60: 4709-4713.
6. Yang F, Li X, Sharma M, Sasaki CY, Longo DL, Lim B et al. Linking beta-catenin to androgen-signaling pathway. J Biol Chem 2002; 277: 11336-11344.
7. Mulholland DJ, Cheng H, Reid K, Rennie PS, Nelson CC. The androgen receptor can promote beta-catenin nuclear transloca-tion independently of adenomatous polyposis coli. J Biol Chem 2002; 277: 17933-17943.
8. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell 2006; 127: 469-480.
9. MacDonald BT, Tamai K, He X. Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell 2009; 17: 9-26.
10. Chesire DR, Isaacs WB. Beta-catenin signaling in prostate cancer: an early perspective. Endocr Relat Cancer 2003; 10: 537-560.
11. Doble BW, Woodgett JR. GSK-3: tricks of the trade for a multitasking kinase. J Cell Sci 2003; 116: 1175-1186.
12. Sharma M, Chuang WW, Sun Z. Phosphatidylinositol 3-kinase/Akt stimulates androgen pathway through GSK3beta inhibition and nuclear beta-catenin accumulation. J Biol Chem 2002; 277: 30935-30941.
13. Ohigashi T, Mizuno R, Nakashima J, Marumo K, Murai M. Inhibition of Wnt signaling downregulates Akt activity and induces chemosensitivity in PTEN-mutated prostate cancer cells. Prostate 2005; 62: 61-68.
14. Mulholland DJ, Dedhar S, Wu H, Nelson CC. PTEN and GSK3beta: key regulators of progression to androgen-indepen-dent prostate cancer. Oncogene 2006; 25: 329-337.
15. Yardy GW, Brewster SF. Wnt signalling and prostate cancer. Prostate Cancer Prostatic Dis 2005; 8: 119-126.
16. Chesire DR, Ewing CM, Gage WR, Isaacs WB. In vitro evidence for complex modes of nuclear beta-catenin signaling during prostate growth and tumorigenesis. Oncogene 2002; 21: 2679-2694.
17. de la Taille A, Rubin MA, Chen MW, Vacherot F, de Medina SG, Burchardt M et al. Beta-catenin-related anomalies in apoptosis-resistant and hormone-refractory prostate cancer cells. Clin Cancer Res 2003; 9: 1801-1807.
18. Chen G, Shukeir N, Potti A, Sircar K, Aprikian A, Goltzman D et al. Up-regulation of Wnt-1 and beta-catenin production in patients with advanced metastatic prostate carcinoma: potential pathogenetic and prognostic implications. Cancer 2004; 101: 1345-1356.
19. Sharma RA, Gescher AJ, Steward WP. Curcumin: the story so far. Eur J Cancer 2005; 41: 1955-1968.
20. Aggarwal BB. Prostate cancer and curcumin: add spice to your life. Cancer Biol Ther 2008; 7: 1436-1440.
21. Dorai T, Gehani N, Katz A. Therapeutic potential of curcumin in human prostate cancer-I. Curcumin induces apoptosis in both androgen-dependent and androgen-independent prostate cancer cells. Prostate Cancer Prostatic Dis 2000; 3: 84-93.
22. Nakamura K, Yasunaga Y, Segawa T, Ko D, Moul JW, Srivastava S et al. Curcumin down-regulates AR gene expression and activation in prostate cancer cell lines. Int J Oncol 2002; 21: 825-830.
23. Tsui KH, Feng TH, Lin CM, Chang PL, Juang HH. Curcumin blocks the activation of androgen and interlukin-6 on prostate-specific antigen expression in human prostatic carcinoma cells. J Androl 2008; 29: 661-668.
24. Shi Q, Shih CC, Lee KH. Novel anti-prostate cancer curcumin analogues that enhance androgen receptor degradation activity. Anticancer Agents Med Chem 2009; 9: 904-912.
25. Lin J, Adam RM, Santiestevan E, Freeman MR. The phospha-tidylinositol 3-kinase pathway is a dominant growth factor-activated cell survival pathway in LNCaP human prostate carcinoma cells. Cancer Res 1999; 59: 2891-2897.
26. Aggarwal S, Ichikawa H, Takada Y, Sandur SK, Shishodia S, Aggarwal BB. Curcumin (diferuloylmethane) down-regulates expression of cell proliferation and antiapoptotic and metastatic gene products through suppression of IkappaBalpha kinase and Akt activation. Mol Pharmacol 2006; 69: 195-206.
27. Shankar S, Srivastava RK. Involvement of Bcl-2 family members, phosphatidylinositol 3-kinase/AKT and mitochondrial p53 in curcumin (diferulolylmethane)-induced apoptosis in prostate cancer. Int J Oncol 2007; 30: 905-918.
28. Yu S, Shen G, Khor TO, Kim JH, Kong AN. Curcumin inhibits Akt/mammalian target of rapamycin signaling through protein phosphatase-dependent mechanism. Mol Cancer Ther 2008; 7: 2609-2620.
29. Mani A, Gelmann EP. The ubiquitin-proteasome pathway and its role in cancer. J Clin Oncol 2005; 23: 4776-4789.